Oragenics will start a second phase I clinical trial of SMaRT replacement therapy, a topical treatment that has the potential to offer lifelong protection against dental caries, according to the company.
The company has retained PRA International as the clinical research organization for clinical trials management services related to the clinical trial, which is currently set to begin in the first quarter of 2011.
SMaRT replacement therapy is designed to be a painless, one-time, five-minute topical treatment applied to the teeth, according to the company. It is based on the creation of a genetically modified strain of bacteria that colonizes in the oral cavity and replaces native decay-causing bacteria.
This technology was developed by Oragenics' Chief Scientific Officer Jeffrey Hillman, DMD, PhD, during more than 25 years of research that began at the Forsyth Institute and continued at the University of Florida, the company said.
Copyright © 2011 DrBicuspid.com
.hpp4JFpXkV.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
.hpp4JFpXkV.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
